[go: up one dir, main page]

EP3700936A4 - Anti-glyco-muc1-antikörper und ihre verwendungen - Google Patents

Anti-glyco-muc1-antikörper und ihre verwendungen Download PDF

Info

Publication number
EP3700936A4
EP3700936A4 EP17929557.1A EP17929557A EP3700936A4 EP 3700936 A4 EP3700936 A4 EP 3700936A4 EP 17929557 A EP17929557 A EP 17929557A EP 3700936 A4 EP3700936 A4 EP 3700936A4
Authority
EP
European Patent Office
Prior art keywords
glyco
muc1 antibodies
muc1
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17929557.1A
Other languages
English (en)
French (fr)
Other versions
EP3700936A1 (de
Inventor
Thayer White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Go Therapeutics Inc
Original Assignee
Go Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Go Therapeutics Inc filed Critical Go Therapeutics Inc
Publication of EP3700936A1 publication Critical patent/EP3700936A1/de
Publication of EP3700936A4 publication Critical patent/EP3700936A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
EP17929557.1A 2017-10-24 2017-10-24 Anti-glyco-muc1-antikörper und ihre verwendungen Pending EP3700936A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/058036 WO2019083506A1 (en) 2017-10-24 2017-10-24 ANTI-GLYCO-MUC1 ANTIBODIES AND USES THEREOF

Publications (2)

Publication Number Publication Date
EP3700936A1 EP3700936A1 (de) 2020-09-02
EP3700936A4 true EP3700936A4 (de) 2021-05-26

Family

ID=66247577

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17929557.1A Pending EP3700936A4 (de) 2017-10-24 2017-10-24 Anti-glyco-muc1-antikörper und ihre verwendungen

Country Status (10)

Country Link
EP (1) EP3700936A4 (de)
JP (2) JP7358367B2 (de)
KR (2) KR20230165874A (de)
CN (1) CN111479828B (de)
AU (1) AU2017436815A1 (de)
BR (1) BR112020008001A2 (de)
CA (1) CA3078812A1 (de)
IL (1) IL274202A (de)
MX (1) MX2020004220A (de)
WO (1) WO2019083506A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114796498A (zh) * 2022-01-27 2022-07-29 中国农业大学 抑制muc1糖基化修饰的物质在提高乳腺癌细胞对抗乳腺癌药物的敏感度中的应用
TW202444432A (zh) * 2023-04-13 2024-11-16 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｅｇｆｒ和ｍｕｃ１的抗原結合分子、其藥物偶聯物及其醫藥用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005474A1 (en) * 2003-01-23 2015-01-01 Glycotope Gmbh Recognition molecules for the treatment and detection of tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500828A (ja) * 2000-03-30 2004-01-15 ダイアックス　コーポレーション Ｍｕｃｉｎ−１特異的結合メンバー及びその使用方法
EP2014302A1 (de) * 2007-07-12 2009-01-14 Institut Curie Für das Tn-Antigen zur Behandlung von Krebs spezifischer Antikörper
JP5532401B2 (ja) * 2007-12-05 2014-06-25 協和発酵キリン株式会社 ヘパリン結合上皮細胞増殖因子様増殖因子に結合するモノクローナル抗体
CA2741798A1 (en) * 2008-10-28 2010-05-06 Shionogi & Co., Ltd. Anti-muc1 antibody
EP2281844A1 (de) * 2009-07-31 2011-02-09 Glycotope GmbH MUC-1-Antikörper
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
US10239950B2 (en) * 2014-04-28 2019-03-26 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150005474A1 (en) * 2003-01-23 2015-01-01 Glycotope Gmbh Recognition molecules for the treatment and detection of tumors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1993, FONTENOT: "Synthesis of large multideterminant peptide immunogens using a poly-proline beta-turn helix motif", XP055796187, Database accession no. PREV199497079884 *

Also Published As

Publication number Publication date
IL274202A (en) 2020-06-30
KR20230165874A (ko) 2023-12-05
EP3700936A1 (de) 2020-09-02
MX2020004220A (es) 2020-10-05
BR112020008001A2 (pt) 2020-10-20
KR102608763B1 (ko) 2023-11-30
JP2021510307A (ja) 2021-04-22
CN111479828B (zh) 2024-07-05
CN111479828A (zh) 2020-07-31
JP7358367B2 (ja) 2023-10-10
KR20200067885A (ko) 2020-06-12
CA3078812A1 (en) 2019-05-02
JP2024001073A (ja) 2024-01-09
AU2017436815A1 (en) 2020-04-23
WO2019083506A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
IL290842A (en) Anti-cd73 antibodies and uses thereof
EP3723803A4 (de) Anti-trem2-antikörper und zugehörige verfahren
IL280648A (en) Anti-galectin-9 antibodies and their uses
EP3596119A4 (de) Anti-phf-tau-antikörper und verwendungen davon
IL271477A (en) Anti-cd166 antibodies and their uses
EP3572427A4 (de) Auf bcma abzielender antikörper und dessen verwendung
TWI799432B (zh) 抗ctla-4抗體及其用途
IL268734A (en) Anti-LAG-3 antibodies and uses thereof
EP3325513A4 (de) Anti-pd-l1-antikörper und verwendungen davon
EP3400243A4 (de) Anti-pd-l1-antikörper und verwendungen davon
EP3684812A4 (de) Anti-ctla4-antikörper und verwendungen davon
EP3891183A4 (de) Anti-claudin-antikörper und verwendungen dafür
IL269134A (en) Antibodies against PAR2 and their use
EP3645563A4 (de) Anti-fam19a5-antikörper und verwendungen davon
EP3658185A4 (de) Anti-tim-3-antikörper und verwendungen davon
EP3735427A4 (de) Anti-mct1-antikörper und verwendungen davon
IL273157A (en) Antibodies specific to AXL and their uses
EP3790586A4 (de) Anti-dll3-antikörper und verwendungen davon
EP3567054A4 (de) Anti-alpha-syn-antikörper und verwendung davon
IL272476A (en) Anti-Apelin antibodies and their uses
EP3675898A4 (de) Anti-lag-3-antikörper und verwendungen davon
EP3402520A4 (de) Anti-pd-1-antikörper und verwendungen davon
EP3529273A4 (de) Anti-o1-antikörper und verwendungen davon
EP3496748A4 (de) Anti-o2-antikörper und verwendungen davon
EP3580236A4 (de) Anti-g-csf-antikörper und verwendungen dafür

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40025649

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210429

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/30 20060101AFI20210422BHEP

Ipc: G01N 33/574 20060101ALI20210422BHEP